Print Friendly, PDF & Email

Sheep anti Human Glypican-3 (GPC3)

Catalogue number: X2395P

Product Type Polyclonal Antibody
Units500 µg
Species reactivity Human
Application IHC (Paraffin)
Western Blotting

Glypican-3 encodes a putative extracellular proteoglycan that is inferred to play an important role in growth control in embryonic mesodermal tissues in which it is selectively expressed. It appears to form a complex with insulin-like growth factor and hence modulate IGF2 action. Glypican-3 is the human homolog of OCI-5, a GPI-linked proteoglycan first isolated from rat intestine. Originally identified as the molecular basis for Simpson-Golabi-Behmel syndrome (SGBS) also called Simpson dysmorphia syndrome (SDYS).

Synonyms: GPC3, GPC-3, OCI5, OCI-5, GTR2-2, MXR7


Immunogen: C terminal recombinant protein (~70aa) which does not overlap with clone 1G12 epitope)


Product Form: Unconjugated

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Purification Method: Total IgG

Concentration: See vial for concentration

Antibody can be used for immunohistochemistry on paraffin-embedded tissues (10 µg/ml) and Western blotting (5-10 µg/ml). Optimal concentration should be evaluated by serial dilutions.

Functional Analysis: Immunohistochemistry

Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles

Product Stability: Products are stable for one year from purchase when stored properly

Ship Conditions: Ship at ambient temperature, freeze upon arrival

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.

1. Lai, J.P., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47, 1211-1222. 2. Zynger, D.L., et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am. J. Clin. Pathol. 2008, 130, 224-230. 3. Anatelli, F., et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol. 2008, 130, 219-223. 4. Yamanaka, K., et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007, 73, 389-394. 5. Filmus, J., et al. Glypicans. Genome Biol. 2008, 9, 224. 6. Baumhoer, D., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 2008, 129, 899-906. 7. Capurro, M.I., et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 2008, 14, 700-711. 8. Motomura, Y., et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int. J. Oncol. 2008, 32, 985-990. 9. Cheng, W., et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29, 1319-1326.

Protein Reference(s)

Database Name: UniProt

Accession number: P51654

Species Accession: Human

Safety Datasheet(s) for this product:
Sodium Azide

Sheep anti Human Glypican-3 (GPC3)



Contact us

Exalpha Biologicals, Inc.
2 Shaker Road, Unit B101
Shirley, MA 01464
Phone: 978-425-1370